342 related articles for article (PubMed ID: 15252144)
1. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Duan Z; Brakora KA; Seiden MV
Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
[TBL] [Abstract][Full Text] [Related]
2. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
Ren L; Xiao L; Hu J
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
4. Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes.
Xiao L; Gao R; Lu S; Ren L; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):735-7. PubMed ID: 17357504
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
McCorkle JR; Gorski JW; Liu J; Riggs MB; McDowell AB; Lin N; Wang C; Ueland FR; Kolesar JM
PLoS One; 2021; 16(8):e0254205. PubMed ID: 34347777
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
7. Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.
Yang Y; Wang Z; Li M; Lu S
J Huazhong Univ Sci Technolog Med Sci; 2009 Apr; 29(2):239-42. PubMed ID: 19399413
[TBL] [Abstract][Full Text] [Related]
8. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
9. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
11. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
12. ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
Meng X; Wang G; Liu P; Hou J; Jin Y; Yu Y; Bai J; Chen F; Sun W; Fu S
Respirology; 2011 Nov; 16(8):1228-34. PubMed ID: 21883677
[TBL] [Abstract][Full Text] [Related]
13. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
14. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Christie EL; Pattnaik S; Beach J; Copeland A; Rashoo N; Fereday S; Hendley J; Alsop K; Brady SL; Lamb G; Pandey A; deFazio A; Thorne H; Bild A; Bowtell DDL
Nat Commun; 2019 Mar; 10(1):1295. PubMed ID: 30894541
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Vaidyanathan A; Sawers L; Gannon AL; Chakravarty P; Scott AL; Bray SE; Ferguson MJ; Smith G
Br J Cancer; 2016 Aug; 115(4):431-41. PubMed ID: 27415012
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
17. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60).
Kachalaki S; Baradaran B; Majidi J; Yousefi M; Shanehbandi D; Mohammadinejad S; Mansoori B
Biomed Pharmacother; 2015 Oct; 75():100-4. PubMed ID: 26463638
[TBL] [Abstract][Full Text] [Related]
18. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
19. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
[TBL] [Abstract][Full Text] [Related]
20. Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma.
Koh I; Hinoi T; Sentani K; Hirata E; Nosaka S; Niitsu H; Miguchi M; Adachi T; Yasui W; Ohdan H; Kudo Y
Cancer Med; 2016 Jul; 5(7):1546-55. PubMed ID: 27060927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
